Dr. Qu Zhican of Nanolattix Invited to Attend ADC & Novel Conjugates Partnering & Investment Summit in the U.S.
Release time:
2025-09-22
On September 9th, Eastern Time, the ADC & Novel Conjugates Partnering & Investment Summit, a focal event in the global ADC (Antibody-Drug Conjugate) field, officially commenced in Boston, USA. Dr. Qu Zhican, Chairman of Nanolattix Biotechnology Co., Ltd., and Elizabeth Wu, Head of International Business, were invited to attend.
Dr. Qu Zhican presented China’s cutting-edge breakthroughs in biomedicine to the international industry, providing a comprehensive overview of Nanolattix’s innovations achieved through its independently developed BioLattix bio-matrix technology platform. Currently, Nanolattix has established over ten ADC and RDC drug R&D pipelines targeting major disease areas based on this platform. Among them, the core drug T320-ADC is undergoing global multi-center clinical trials, with the first patient successfully dosed in June this year. Additionally, the first-in-class bispecific ADC drug B836 and the RDC drug RT01 have shown significant progress in preclinical studies.
The summit focused intensively on the entire industrial chain development of ADC drugs, bringing together representatives from over a hundred upstream and downstream companies, including multinational pharmaceutical leaders, emerging biotech firms, and seasoned investment institutions. Representatives from pioneering international companies such as Johnson & Johnson and Merck also took the stage to share insights on the latest technological advances and future directions in the global ADC field.
Nanolattix’s participation in this premier international industry forum not only demonstrated the innovative capabilities of Chinese companies in cutting-edge drug R&D but also signified that China’s innovative drug technology has become deeply integrated into the new global competitive landscape of ADC. Nanolattix is committed to facilitating a critical transition for Chinese biopharmaceutical enterprises—from “following” to “keeping pace” and ultimately to “leading”—through differentiated pipeline strategies and breakthrough advancements, thereby continuously enhancing their voice and influence on the global biopharmaceutical stage.
Tag:
recommend News
Share
